AG1343 oral HIV protease inhibitor: Will begin this week an extension of U.K. Phase II testing into the U.S., in a trial in 30 patients who will receive one of

Agouron Pharmaceuticals Inc. (AGPH), La Jolla, Calif. Product: AG1343 oral HIV protease inhibitor Indication: HIV infection Status: Will begin this week an extension of U.K. Phase II testing into the ...